Form 4: Zenas BioPharma Executive Acquires Stock Options

Joseph L. Farmer, President and COO of Zenas BioPharma, reports the acquisition of stock options.

Summary

• On September 12, 2024, Joseph L. Farmer, President and Chief Operating Officer of Zenas BioPharma, acquired stock options for 206,000 shares of common stock.
• The exercise price of these options is $17.
• The options vest over a period of 4 years, starting with 25% on September 12, 2025, and the remainder in equal monthly installments over the following 36 months, contingent upon continued service.
• Following this transaction, Farmer directly owns derivative securities for 206,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options to a key executive is generally viewed as a positive sign, indicating confidence in the company's future prospects and aligning management's interests with those of shareholders.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to continued service, incentivizing the executive to remain with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their executives.
• The vesting schedule and exercise price are generally aligned with industry norms to retain and motivate key personnel.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning executive interests with shareholder value.
• Employees may see this as a sign of company growth and stability.

Key Dates